Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

BACKGROUND: We previously demonstrated that brentuximab vedotin (BV) used as second-line therapy in patients with Hodgkin lymphoma is a tolerable and effective bridge to autologous hematopoietic cell transplantation (AHCT). Here, we report the post-AHCT outcomes of patients treated with second-line...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Herrera, A F, Palmer, J, Martin, P, Armenian, S, Tsai, N -C, Kennedy, N, Sahebi, F, Cao, T, Budde, L E, Mei, M, Siddiqi, T, Popplewell, L, Rosen, S T, Kwak, L W, Nademanee, A, Forman, S J, Chen, R
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889038/
https://ncbi.nlm.nih.gov/pubmed/29272364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx791
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados